Aligos Therapeutics vs Upstream Bio
Upstream Bio is the larger business, with $2.9m of revenue in fiscal 2025 against $2.2m for Aligos Therapeutics (1.3 times as much). Upstream Bio grew faster (20.4% against -39.5%). Aligos Therapeutics kept more of each dollar of sales as profit: a net margin of -1106.7% against -5026.0%.
| Latest fiscal year | Aligos TherapeuticsALGS, 2025 | Upstream BioUPB, 2025 |
|---|---|---|
| Revenue | $2.2m | $2.9m |
| Revenue growth | -39.5% | 20.4% |
| Net income | −$24.2m | −$143m |
| Operating margin | — | -5618.8% |
| Net margin | -1106.7% | -5026.0% |
| Return on equity | -196.9% | -35.4% |
| Free cash flow | −$82.5m | −$133m |
| Cash | $18.3m | $102m |
| Total debt | $0 | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 82 | 75 |
| Market value | $29.6m | $182m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 15 sales |